$KALA
KALA BIO, Inc.

2021 Form 10-K Financial Statement

#000155837022004624 Filed on March 29, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $11.24M $2.238M $6.362M
YoY Change 76.67% 89.66% 4.74%
Cost Of Revenue $4.097M $1.360M $3.170M
YoY Change 29.24% 81.33% 57.71%
Gross Profit $7.143M $880.0K $3.190M
YoY Change 123.92% 104.65% -21.62%
Gross Profit Margin 63.55% 39.32% 50.14%
Selling, General & Admin $105.1M $26.47M $81.07M
YoY Change 29.6% 82.68% 24.69%
% of Gross Profit 1470.82% 3007.95% 2541.32%
Research & Development $11.52M $3.400M $18.35M
YoY Change -37.25% -44.63% -32.71%
% of Gross Profit 161.21% 386.36% 575.3%
Depreciation & Amortization $975.0K $240.0K $912.0K
YoY Change 6.91% 4.35% 8.19%
% of Gross Profit 13.65% 27.27% 28.59%
Operating Expenses $141.5M $31.22M $102.6M
YoY Change 37.91% 46.05% 8.8%
Operating Profit -$130.2M -$30.34M -$96.23M
YoY Change 35.35% 44.85% 9.08%
Interest Expense $8.380M -$2.130M $8.589M
YoY Change -2.43% 21.02% 1.29%
% of Operating Profit
Other Income/Expense, Net -$12.36M
YoY Change
Pretax Income -$142.6M -$31.11M -$104.3M
YoY Change 36.69% 41.67% 10.58%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$142.6M -$31.11M -$104.3M
YoY Change 36.69% 41.67% 10.58%
Net Earnings / Revenue -1268.73% -1390.08% -1639.85%
Basic Earnings Per Share -$2.19 -$1.99
Diluted Earnings Per Share -$2.19 -$546.2K -$1.99
COMMON SHARES
Basic Shares Outstanding 65.20M 56.08M 52.38M
Diluted Shares Outstanding 65.20M 52.38M

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $92.14M $153.5M $153.5M
YoY Change -39.98% 79.74% 79.74%
Cash & Equivalents $77.26M
Short-Term Investments $0.00 $76.30M $76.30M
Other Short-Term Assets $6.136M $3.000M $2.700M
YoY Change 127.26% -21.05% 17.39%
Inventory $8.639M $5.229M $5.200M
Prepaid Expenses
Receivables $15.35M $9.604M $9.600M
Other Receivables $2.110M $0.00 $300.0K
Total Short-Term Assets $124.4M $171.4M $171.4M
YoY Change -27.44% 62.47% 62.46%
LONG-TERM ASSETS
Property, Plant & Equipment $4.021M $3.166M $31.00M
YoY Change -87.03% 17.35% -4.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $11.04M $19.20M $19.20M
YoY Change -42.5% 17.07% 17.07%
Total Long-Term Assets $15.06M $50.23M $50.20M
YoY Change -70.0% 2.84% 2.87%
TOTAL ASSETS
Total Short-Term Assets $124.4M $171.4M $171.4M
Total Long-Term Assets $15.06M $50.23M $50.20M
Total Assets $139.4M $221.6M $221.6M
YoY Change -37.08% 43.6% 43.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.899M $1.724M $1.700M
YoY Change 188.18% -31.53% -32.0%
Accrued Expenses $21.70M $18.97M $20.50M
YoY Change 5.84% -9.36% -8.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $37.42M $22.23M $22.20M
YoY Change 68.57% -10.29% -10.48%
LONG-TERM LIABILITIES
Long-Term Debt $78.93M $72.24M $72.20M
YoY Change 9.32% 1.49% 1.4%
Other Long-Term Liabilities $6.272M $27.10M $27.10M
YoY Change -76.86% -5.57% -5.57%
Total Long-Term Liabilities $85.20M $99.39M $99.30M
YoY Change -14.2% -0.47% -0.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $37.42M $22.23M $22.20M
Total Long-Term Liabilities $85.20M $99.39M $99.30M
Total Liabilities $122.6M $121.6M $121.6M
YoY Change 0.84% -2.42% -2.41%
SHAREHOLDERS EQUITY
Retained Earnings -$399.8M
YoY Change 35.31%
Common Stock $59.00K
YoY Change 63.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.80M $100.0M $100.0M
YoY Change
Total Liabilities & Shareholders Equity $139.4M $221.6M $221.6M
YoY Change -37.08% 43.6% 43.62%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income -$142.6M -$31.11M -$104.3M
YoY Change 36.69% 41.67% 10.58%
Depreciation, Depletion And Amortization $975.0K $240.0K $912.0K
YoY Change 6.91% 4.35% 8.19%
Cash From Operating Activities -$108.2M -$25.91M -$90.69M
YoY Change 19.34% 42.28% -2.19%
INVESTING ACTIVITIES
Capital Expenditures -$886.0K -$480.0K -$1.940M
YoY Change -54.33% 152.63% 44.78%
Acquisitions $4.653M
YoY Change
Other Investing Activities $71.69M $37.32M -$76.27M
YoY Change -193.99%
Cash From Investing Activities $70.80M $36.84M -$78.21M
YoY Change -190.53% -19489.47% 5758.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $41.23M $158.6M
YoY Change -74.0% 1781.98%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 42.55M 20.72M 160.6M
YoY Change -73.51% 229.41% 1688.33%
NET CHANGE
Cash From Operating Activities -108.2M -25.91M -90.69M
Cash From Investing Activities 70.80M 36.84M -78.21M
Cash From Financing Activities 42.55M 20.72M 160.6M
Net Change In Cash 5.122M 31.65M -8.275M
YoY Change -161.9% -361.35% -90.27%
FREE CASH FLOW
Cash From Operating Activities -$108.2M -$25.91M -$90.69M
Capital Expenditures -$886.0K -$480.0K -$1.940M
Free Cash Flow -$107.3M -$25.43M -$88.75M
YoY Change 20.95% 41.12% -2.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65202832
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52377526
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001479419
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65202832
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52377526
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65500275
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58915375
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.19
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.99
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65500275
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58915375
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.19
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.99
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-38150
CY2021 dei Entity Registrant Name
EntityRegistrantName
KALA PHARMACEUTICALS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-0604595
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
1167 Massachusetts Avenue
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Arlington,
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02476
CY2021 dei City Area Code
CityAreaCode
781
CY2021 dei Local Phone Number
LocalPhoneNumber
996-5252
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2021 dei Trading Symbol
TradingSymbol
KALA
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
254300000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
72594005
CY2021 dei Auditor Firm
AuditorFirmId
34
CY2021 dei Auditor Name
AuditorName
Deloitte & Touche LLP
CY2021 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92136000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77264000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
76276000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
2042000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15345000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9604000
CY2021Q4 us-gaap Inventory Net
InventoryNet
8639000
CY2020Q4 us-gaap Inventory Net
InventoryNet
5229000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6204000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3006000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
124366000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
171379000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2722000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3166000
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
9578000
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
6219000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1299000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27853000
CY2021Q4 kala Restricted Cash And Other Assets Noncurrent
RestrictedCashAndOtherAssetsNoncurrent
1462000
CY2020Q4 kala Restricted Cash And Other Assets Noncurrent
RestrictedCashAndOtherAssetsNoncurrent
12989000
CY2021Q4 us-gaap Assets
Assets
139427000
CY2020Q4 us-gaap Assets
Assets
221606000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4899000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1724000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20986000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18971000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
711000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1530000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
3817000
CY2021Q4 kala Deferred Purchase Consideration Current
DeferredPurchaseConsiderationCurrent
7009000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
37422000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22225000
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
548000
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
27143000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
78929000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
72243000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
4841000
CY2021Q4 kala Deferred Purchase Consideration Non Current
DeferredPurchaseConsiderationNonCurrent
883000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
85201000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
99386000
CY2021Q4 us-gaap Liabilities
Liabilities
122623000
CY2020Q4 us-gaap Liabilities
Liabilities
121611000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65500275
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58915375
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
66000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
59000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
559126000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
499715000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-542388000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-399783000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
16804000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
99995000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
139427000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
221606000
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11240000
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6362000
CY2021 kala Product Revenue Cost
ProductRevenueCost
4097000
CY2020 kala Product Revenue Cost
ProductRevenueCost
3173000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
105061000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
81068000
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
11515000
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
18352000
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
26617000
CY2021 kala Gain On Fair Value Re Measurement Of Deferred Purchase Consideration
GainOnFairValueReMeasurementOfDeferredPurchaseConsideration
5805000
CY2021 us-gaap Operating Expenses
OperatingExpenses
141485000
CY2020 us-gaap Operating Expenses
OperatingExpenses
102593000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-130245000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-96231000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
104000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
493000
CY2021 us-gaap Interest Expense
InterestExpense
8380000
CY2020 us-gaap Interest Expense
InterestExpense
8589000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-5395000
CY2021 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
1311000
CY2021 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-12360000
CY2020 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-8096000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-142605000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-104327000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.19
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.99
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65202832
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52377526
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-142605000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-104327000
CY2021 kala Other Comprehensive Income Available For Sale Securities Adjustments Net Of Tax Portions Attributable To Parent
OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentsNetOfTaxPortionsAttributableToParent
-4000
CY2020 kala Other Comprehensive Income Available For Sale Securities Adjustments Net Of Tax Portions Attributable To Parent
OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentsNetOfTaxPortionsAttributableToParent
4000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-142609000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-104323000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
29692000
CY2020 kala Payments Of Stock Issuance Costs At Market Offering
PaymentsOfStockIssuanceCostsAtMarketOffering
1026000
CY2020 kala Stock Issued During Period Value New Issues At Market
StockIssuedDuringPeriodValueNewIssuesAtMarket
33134000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1087000
CY2020 us-gaap Expense Related To Distribution Or Servicing And Underwriting Fees
ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
8475000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
125423000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1016000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13966000
CY2020 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-104327000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
99995000
CY2021 kala Payments Of Stock Issuance Costs At Market Offering
PaymentsOfStockIssuanceCostsAtMarketOffering
1176000
CY2021 kala Stock Issued During Period Value New Issues At Market
StockIssuedDuringPeriodValueNewIssuesAtMarket
41232000
CY2020Q4 kala Deferred Tax Assets Tax Deferred Lease Liabilities
DeferredTaxAssetsTaxDeferredLeaseLiabilities
8152000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
975000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
912000
CY2021 kala Non Cash Operating Lease
NonCashOperatingLease
1335000
CY2020 kala Non Cash Operating Lease
NonCashOperatingLease
1928000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
248000
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1337000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16600000
CY2021 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-4000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-142605000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
16804000
CY2021 us-gaap Profit Loss
ProfitLoss
-142605000
CY2020 us-gaap Profit Loss
ProfitLoss
-104327000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-5395000
CY2021 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
1311000
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
26617000
CY2021 kala Gain On Fair Value Re Measurement Of Deferred Purchase Consideration
GainOnFairValueReMeasurementOfDeferredPurchaseConsideration
5805000
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1519000
CY2020 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1059000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
16088000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
13312000
CY2021 kala Amortization Of Discount On Available For Sale Securities
AmortizationOfDiscountOnAvailableForSaleSecurities
22000
CY2020 kala Amortization Of Discount On Available For Sale Securities
AmortizationOfDiscountOnAvailableForSaleSecurities
-5000
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-151000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5756000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1959000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2859000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-818000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6257000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2368000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3231000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-924000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1714000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1763000
CY2021 kala Increase Decrease In Lease And Other Liabilities Noncurrent
IncreaseDecreaseInLeaseAndOtherLiabilitiesNoncurrent
-689000
CY2020 kala Increase Decrease In Lease And Other Liabilities Noncurrent
IncreaseDecreaseInLeaseAndOtherLiabilitiesNoncurrent
-1295000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-108235000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90694000
CY2021 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
4653000
CY2021 kala Payments To Acquire Property Plant And Equipment And Other Assets
PaymentsToAcquirePropertyPlantAndEquipmentAndOtherAssets
886000
CY2020 kala Payments To Acquire Property Plant And Equipment And Other Assets
PaymentsToAcquirePropertyPlantAndEquipmentAndOtherAssets
1942000
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
92000
CY2020 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
113592000
CY2021 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
76250000
CY2020 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
37325000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
70803000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-78209000
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
2218000
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
77782000
CY2021 kala Payment Of Principal On Venture Debt Facility
PaymentOfPrincipalOnVentureDebtFacility
78010000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
41232000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
158557000
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
35000
CY2020 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
32000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1585000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2103000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42554000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
160628000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5122000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8275000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
89756000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
98031000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
94878000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
89756000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
94878000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
89756000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2742000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
12492000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92136000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77264000
CY2021 kala Capital Expenditures Incurred But Not Yet Paid Accrued Expenses
CapitalExpendituresIncurredButNotYetPaidAccruedExpenses
139000
CY2020 kala Capital Expenditures Incurred But Not Yet Paid Accrued Expenses
CapitalExpendituresIncurredButNotYetPaidAccruedExpenses
130000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
6837000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
7528000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1210000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-142605000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-104327000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-108235000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90694000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<b style="font-weight:bold;">Use of Estimates—</b> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expense, and related disclosures. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. Estimates and assumptions relied upon in preparing these consolidated financial statements relate to, but are not limited to, revenue recognition, inventory, the present value of lease liabilities and the corresponding right-of-use assets, the fair value of warrants, contingent consideration and acquired in-process research and development (“IPR&amp;D”), stock-based compensation, accrued expenses and the recoverability of the Company’s net deferred tax assets and related valuation allowance. Actual results may differ from these estimates under different assumptions or conditions.
CY2021 kala Payment Typically Received Minimum
PaymentTypicallyReceivedMinimum
P70D
CY2021 kala Payment Typically Received Maximum
PaymentTypicallyReceivedMaximum
P90D
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
26617000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Cash and Concentration of Credit Risk</b>—Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. Periodically, the Company maintains cash, cash equivalents, short-term investments in accredited financial institutions in excess of federally insured limits. The Company deposits its cash, cash equivalents, short-term investments in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Three Customers comprised 10% or more of the Company’s accounts receivable balance as of December 31, 2021 and 2020. These Customers comprised 44%, 31% and 24% of the accounts receivable balance, respectively, as of December 31, 2021 and 39%, 33% and 25% of the accounts receivable balance, respectively, as of December 31, 2020. To date, losses with respect to the collection of the Company’s accounts receivable have been <i style="font-style:italic;background:#ffffff;">de minimis </i>and the Company believes that its entire accounts receivable balances is collectible as of December 31, 2021. The same three Customers comprised 10% or more of the Company’s revenue during the years ended December 31, 2021 and 2020. These Customers comprised 48%, 29% and 22% of revenue, respectively, during the year ended December 31, 2021 and 40%, 29% and 28% of revenue, respectively, during the year ended December 31, 2020. The Company has no financial instruments with off-balance sheet risk of loss.</p>
CY2021 kala Number Of Counter Parties
NumberOfCounterParties
3
CY2021 kala Number Of Counter Parties
NumberOfCounterParties
3
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
2042000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
700000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
12492000
CY2020 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2021 kala Gain On Fair Value Re Measurement Of Deferred Purchase Consideration
GainOnFairValueReMeasurementOfDeferredPurchaseConsideration
5805000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
76272000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
76276000
CY2020 kala Investments Contractual Maturity Term
InvestmentsContractualMaturityTerm
P1Y
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1328000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
801000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
9799000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
6437000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7090000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4210000
CY2021Q4 kala Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
18217000
CY2020Q4 kala Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
11448000
CY2021Q4 us-gaap Inventory Net
InventoryNet
8639000
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
9578000
CY2020Q4 us-gaap Inventory Net
InventoryNet
5229000
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
6219000
CY2021Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
2110000
CY2020Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
250000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1307000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1201000
CY2021Q4 kala Prepaid Deposits
PrepaidDeposits
911000
CY2020Q4 kala Prepaid Deposits
PrepaidDeposits
606000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1876000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
949000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6204000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3006000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5583000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6590000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2861000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3424000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2722000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3166000
CY2021 us-gaap Depreciation
Depreciation
933000
CY2020 us-gaap Depreciation
Depreciation
908000
CY2021Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group
AssetsHeldForSaleNotPartOfDisposalGroup
211000
CY2021Q4 kala Accrued Revenue Reserves
AccruedRevenueReserves
10300000
CY2020Q4 kala Accrued Revenue Reserves
AccruedRevenueReserves
5224000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6324000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9676000
CY2021Q4 kala Accrued Commercialization Cost
AccruedCommercializationCost
2134000
CY2020Q4 kala Accrued Commercialization Cost
AccruedCommercializationCost
2103000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
881000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
926000
CY2021Q4 kala Accrued Contract Manufacturing
AccruedContractManufacturing
396000
CY2020Q4 kala Accrued Contract Manufacturing
AccruedContractManufacturing
336000
CY2021Q4 kala Development Costs Current
DevelopmentCostsCurrent
127000
CY2020Q4 kala Development Costs Current
DevelopmentCostsCurrent
154000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
824000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
552000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20986000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18971000
CY2019Q4 kala Number Of Vehicles Leased
NumberOfVehiclesLeased
65
CY2020Q4 us-gaap Line Of Credit
LineOfCredit
450000
CY2021Q4 us-gaap Line Of Credit
LineOfCredit
450000
CY2019Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2021Q4 kala Number Of Additional Vehicles Leased
NumberOfAdditionalVehiclesLeased
54
CY2021 kala Vehicles Leased Term
VehiclesLeasedTerm
P3Y
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
3822000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
4741000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
20000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
2270000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
1848000
CY2021 us-gaap Lease Cost
LeaseCost
6112000
CY2020 us-gaap Lease Cost
LeaseCost
6589000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
7350000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
5981000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y3M18D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.026
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.098
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
10000000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
4445000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
53333000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
22222000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
80000000
CY2021 kala Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
215172
CY2020 kala Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
248505
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65500275
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58915375
CY2021 kala Number Of Votes Per Common Share
NumberOfVotesPerCommonShare
1
CY2021 kala Number Of Directors Granted Per Voting Block Of Outstanding Shares
NumberOfDirectorsGrantedPerVotingBlockOfOutstandingShares
1
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
21971410
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11744473
CY2021 kala Share Based Compensation Arrangement By Share Based Payment Award Award Anniversary
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardAnniversary
P1Y
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.727
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.742
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.796
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.825
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0050
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0139
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0037
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0173
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.63
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.20
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16088000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13312000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
248000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1087000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
406000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2124000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
942222
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
11.70
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
548090
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
11.35
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
813869
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
8.84
CY2021Q4 kala Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Deferred
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferred
88000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-142605000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-104327000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65202832
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52377526
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.19
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.99
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11029971
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9935854
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.230
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.222
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.039
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.013
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.009
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.048
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.012
CY2021 kala Effective Income Tax Rate Reconciliation Impact Of Irc382 Limitation Percent
EffectiveIncomeTaxRateReconciliationImpactOfIrc382LimitationPercent
0.013
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.005
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.009
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.006
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
102935000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
67368000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
8408000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
7413000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
4615000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
5258000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3591000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2398000
CY2021Q4 kala Deferred Tax Assets Tax Deferred Expense Rebates Incentives Trade Discounts And Allowances
DeferredTaxAssetsTaxDeferredExpenseRebatesIncentivesTradeDiscountsAndAllowances
3334000
CY2020Q4 kala Deferred Tax Assets Tax Deferred Expense Rebates Incentives Trade Discounts And Allowances
DeferredTaxAssetsTaxDeferredExpenseRebatesIncentivesTradeDiscountsAndAllowances
2177000
CY2021Q4 kala Deferred Tax Assets Tax Deferred Lease Liabilities
DeferredTaxAssetsTaxDeferredLeaseLiabilities
321000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
1260000
CY2021 kala Annual Minimum Payment Of License Fee
AnnualMinimumPaymentOfLicenseFee
38000
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
2609000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
124464000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
95375000
CY2021Q4 kala Operating Or Finance Lease Right Of Use Asset
OperatingOrFinanceLeaseRightOfUseAsset
331000
CY2020Q4 kala Operating Or Finance Lease Right Of Use Asset
OperatingOrFinanceLeaseRightOfUseAsset
7810000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
331000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
7810000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
124133000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
87565000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
36568000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
17492000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3591000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3591000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2398000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 kala Annual Minimum Payment Of License Fee If Company Achieves First Commercial Sale
AnnualMinimumPaymentOfLicenseFeeIfCompanyAchievesFirstCommercialSale
113000
CY2021Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
131000
CY2021Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
143000
CY2021Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
143000
CY2021Q4 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
178000
CY2021Q4 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
178000
CY2021Q4 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
1240000
CY2021Q4 us-gaap Contractual Obligation
ContractualObligation
2013000
CY2021 kala Purchase Obligations Fiscal Year Maturity Schedule Table Textblock
PurchaseObligationsFiscalYearMaturityScheduleTableTextblock
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Years Ending December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2022 (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">4,044 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6,190 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6,380 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2025 (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">9,370 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2026 (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">7,028 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Thereafter (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">14,411 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total minimum purchase commitments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">47,423 </p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amount presented is net of amounts paid towards the minimum purchase obligation as of December 31, 2021.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Beginning with the contract year July 1, 2025 to June 30, 2026, the minimum contract amounts above are </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">75%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of the actual dollar value of the units ordered for commercial products, in the aggregate, in the contract year immediately prior to the applicable contract year. The table above assumes each contract year beginning July 1, 2025, purchases are 75% of the prior year purchases.</span></td></tr></table><div style="margin-top:12pt;"/>
CY2021Q4 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
4044000
CY2021Q4 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
6190000
CY2021Q4 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
6380000
CY2021Q4 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
9370000
CY2021Q4 us-gaap Purchase Obligation Due In Fifth Year
PurchaseObligationDueInFifthYear
7028000
CY2021Q4 us-gaap Purchase Obligation Due After Fifth Year
PurchaseObligationDueAfterFifthYear
14411000
CY2021Q4 us-gaap Purchase Obligation
PurchaseObligation
47423000
CY2021 kala Minimum Contract Amount Percent
MinimumContractAmountPercent
0.75
CY2021 kala Minimum Contract Amount Percent
MinimumContractAmountPercent
0.75
CY2020Q4 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2021Q4 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
612000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
446000

Files In Submission

Name View Source Status
0001558370-22-004624-index-headers.html Edgar Link pending
0001558370-22-004624-index.html Edgar Link pending
0001558370-22-004624.txt Edgar Link pending
0001558370-22-004624-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kala-20211231.xsd Edgar Link pending
kala-20211231x10k.htm Edgar Link pending
kala-20211231x10k006.jpg Edgar Link pending
kala-20211231x10k007.jpg Edgar Link pending
kala-20211231x10k008.jpg Edgar Link pending
kala-20211231x10k009.jpg Edgar Link pending
kala-20211231x10k010.jpg Edgar Link pending
kala-20211231x10k011.jpg Edgar Link pending
kala-20211231x10k012.jpg Edgar Link pending
kala-20211231x10k013.jpg Edgar Link pending
kala-20211231x10k014.jpg Edgar Link pending
kala-20211231x10k015.jpg Edgar Link pending
kala-20211231x10k016.jpg Edgar Link pending
kala-20211231x10k017.jpg Edgar Link pending
kala-20211231x10k018.jpg Edgar Link pending
kala-20211231x10k020.jpg Edgar Link pending
kala-20211231x10k021.jpg Edgar Link pending
kala-20211231x10k_htm.xml Edgar Link completed
kala-20211231xex10d18.htm Edgar Link pending
kala-20211231xex10d33.htm Edgar Link pending
kala-20211231xex10d35.htm Edgar Link pending
kala-20211231xex21d1.htm Edgar Link pending
kala-20211231xex23d1.htm Edgar Link pending
kala-20211231xex31d1.htm Edgar Link pending
kala-20211231xex31d2.htm Edgar Link pending
kala-20211231xex32d1.htm Edgar Link pending
kala-20211231xex32d2.htm Edgar Link pending
kala-20211231_cal.xml Edgar Link unprocessable
kala-20211231_def.xml Edgar Link unprocessable
kala-20211231_lab.xml Edgar Link unprocessable
kala-20211231_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending